Gilead Sciences’ Chief Executive Officer John Milligan plans to step down at the end of the year, as Gilead continues to struggle with falling sales and profit.
Milligan has spent 28 years at Gilead, serving as CEO the past two years. Milligan will step down from the board at the end of year and John Martin, chairman of the board, will also be departing once a new CEO is named.
Gilead’s board is currently conducting a search for Milligan’s successor.
Read the WSJ coverage